ADMA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AD

Mkt Cap

$2.39B

Volume

1.77M

Next Earnings

November 4th

Loading chart

AD

ADMAADMA Biologics, Inc.

ADMA

Pay with—

Available Balance0.00

AD

Mkt Cap

$2.39B

Volume

1.77M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses.Zacks Investment Research · Oct 9, 2026

Adma Biologics (ADMA) Advances While Market Declines: Some Information for InvestorsAdma Biologics (ADMA) outperformed the broader market on October 8, 2026, rising 1.87% to $10.33 while the S&P 500 declined 0.47%. The infectious disease drug developer has gained 7.3% over the past month and is expected to report EPS of $0.19 (up 18.75% YoY) with revenue of $139.8 million (up 4.16% YoY). The company trades at a Forward P/E of 13.06, a discount to its industry average of 23.26, and currently holds a Zacks Rank of #3 (Hold).Zacks Investment Research · Oct 8, 2026

ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should KnowADMA Biologics has attracted investor attention with shares returning +7.3% over the past month, outperforming the S&P 500's +1.4% gain. The company is expected to post earnings of $0.19 per share for the current quarter (+18.8% YoY) and $0.78 for the fiscal year (+30% YoY). However, with a Zacks Rank #3 (Hold) rating and consensus estimates remaining unchanged over the past month, the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers with a B grade on the Value Style Score.Zacks Investment Research · Oct 8, 2026

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?While brokers give Adma Biologics an average recommendation of 2.00 (Buy) based on five firms' ratings, the article cautions that brokerage recommendations often have positive bias due to institutional vested interests. The company's Zacks Rank is #3 (Hold), as earnings estimates have remained unchanged, suggesting the stock may perform in line with the broader market in the near term.Zacks Investment Research · Sep 8, 2026

BTU IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Peabody Energy Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BTURosen Law Firm is encouraging investors who suffered losses exceeding $100,000 in Peabody Energy Corporation (BTU) to join a securities class action lawsuit. The lawsuit alleges that Peabody Energy provided misleading statements about its Centurion mine operations, with actual Q1 2026 output reaching only 250,000 tons versus previously estimated 700,000 tons. The lead plaintiff deadline is August 24, 2026. Similar class actions are also being pursued against ADMA Biologics and Microvast Holdings.GlobeNewswire Inc. · Aug 9, 2026

ADMA DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMARosen Law Firm reminds investors of the August 10, 2026 deadline to join a securities class action lawsuit against ADMA Biologics. The lawsuit alleges the company made materially false statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls that artificially inflated revenue during the class period from August 9, 2024 to March 25, 2026.GlobeNewswire Inc. · Aug 9, 2026

ADMA 3-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens BermanADMA Biologics is facing a securities fraud class action lawsuit alleging misrepresentations regarding financial condition, revenue recognition, and undisclosed related-party transactions. A short-seller report in March 2026 revealed channel stuffing and improper accounting practices, causing the stock to plunge 31.6% over two trading days. The lawsuit covers the period from August 9, 2024 to March 25, 2026, with a lead plaintiff deadline of August 10, 2026.GlobeNewswire Inc. · Aug 7, 2026

MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ADMAADMA Biologics is facing a securities class action lawsuit alleging the company made false statements regarding undisclosed related party transactions, channel stuffing schemes, and inadequate internal controls. A Culper Research report claimed ADMA's reported 20% growth in 2025 was artificially inflated, with actual revenue declining 3% when adjusted for extended payment terms. The stock declined over 16% following the report, and an additional 13% after a Cantor Fitzgerald downgrade. Investors with substantial losses can seek lead plaintiff status by Monday, August 10, 2026.GlobeNewswire Inc. · Aug 6, 2026

DEADLINE ALERT for FUTU, FSLR, BRCB, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsClass action lawsuits have been filed against four publicly-traded companies for alleged securities fraud. Futu Holdings faces allegations of non-compliance with Chinese regulatory requirements, First Solar allegedly overstated its ability to manage tariff impacts, Black Rock Coffee Bar allegedly misrepresented its expansion strategy and cannibalization effects, and ADMA Biologics allegedly engaged in undisclosed related party transactions and channel stuffing. Investors have until mid-to-late August 2026 to file lead plaintiff motions.GlobeNewswire Inc. · Aug 6, 2026

Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitA class action lawsuit has been filed against ADMA Biologics, Inc. following allegations of channel stuffing and undisclosed related party transactions. Culper Research reported that ADMA induced distributors to stock excess inventory through rebates and extended payment terms to artificially inflate revenue growth. The stock fell 29.1% on the news, and investors have until August 10, 2026 to file a lead plaintiff motion.GlobeNewswire Inc. · Aug 6, 2026

to start trading

AD

ADMAADMA Biologics, Inc.

ADMA

Pay with—

Available Balance0.00

Your PositionYou don't own any ADMA yet.

Related Tickers

Earnings